reinforces the best-in-class characteristics of our clinically validated anti-alpha-syn active immunotherapy for the treatment of Parkinson’s disease,” said Andrea Pfeifer, CEO of AC Immune. “As a ...
AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s DiseaseActive ...
Knee cartilage is not designed for high stress loads. People who are overweight or obese are at a higher risk of developing osteoarthritis because of the extra stress on their knee joints, with many ...
When I was diagnosed with Parkinson’s in August 2019, a doctor told me that Sinemet (Levodopa/Carbidopa), the starter drug of ...
The 78-year-old broadcaster lifted the lid on how he has been coping with the health news, as well as sharing his opinion on ...
Critical Path Institute® (C-Path) today announced a landmark initiative, Gender Equitable Medicines for Parkinson's Disease (GEM-PD), dedicated to globally advancing actionable research on how ...
A team of researchers from the University of Barcelona and the Bellvitge Biomedical Research Institute (IDIBELL) has identified a potential biomarker of Parkinson's disease progression.
Net cash used in operating and investing activities was $45.2 million and $102.5 million for the third quarter and first nine months of 2024, respectively; quarter-end cash and restricted cash positio ...
Analysis suggests that the research and development of DMTs and non-motor therapies will diversify Parkinson's treatment ...
GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...
The researchers note that, "despite the similarities, patients with these diseases have a different prognosis and do not respond to levodopa, the main treatment for Parkinson's disease. Therefore, the ...
The Prix Galien USA Best Startup category recognizes outstanding innovation by therapeutics-focused life science companies that have not yet received their first product approval The award to CervoMed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback